colistimethate sodium


Able Medical


Universal Medical Industry


Able Medical
Concise Prescribing Info
Colistimethate Na
Adults, childn & neonates for serious infections due to selected aerobic gm -ve pathogens in patients w/ limited treatment options. Management of adult & paed chronic pulmonary infections due to Pseudomonas aeruginosa in patients w/ cystic fibrosis.
Dosage/Direction for Use
IV Administer as slow infusion over 30-60 min. Adult & adolescent Maintenance dose: 9 MIU/day [300 mg of colistin base activity (CBA)] in 2-3 divided doses; critically ill patient Administer loading dose of 9 MIU (300 mg of CBA). Patient w/ CrCl <50-30 mL/min 5.5-7.5 MIU (183-250 mg of CBA) daily; <30-10 mL/min 4.5-5.5 MIU (150-183 mg of CBA) daily; <10 mL/min 3.5 MIU (116 mg of CBA) daily. Patient in haemodialysis (HD) No-HD days: 2.25 MIU/day (75 mg of CBA) bid, 2.2-2.3 MIU/day (73-77 mg of CBA) bid; HD days: 3 MIU/day (100 mg of CBA) bid given after HD session. Patient in continuous venovenous haemo(dia)filtration To be given tid. Patient w/ totally implantable venous access device in place Bolus inj up to 2 MIU (68 mg of CBA) in 10 mL given over min of 5 min. Childn weighing >40 kg Use adult dose, <40 kg 75,000-150,000 IU/kg/day (2.5-5 mg of CBA) divided in 3 doses. Childn w/ cystic fibrosis >150,000 IU/kg/day (5 mg of CBA). Intrathecal/intraventricular Adult 125,000 (0.4 mg of CBA)/day via intraventricular route. Administer doses intrathecally not exceeding recommended intraventricular use. Inhalation Adult, adolescent & childn ≥2 yr 1-2 MIU (34-68 mg of CBA) bid-tid [Max dose: 6 MIU/day (200 mg of CBA)]. Childn <2 yr 0.5-1 MIU (17-34 mg of CBA) bid [Max dose: 2 MIU/day (68 mg of CBA)].
Hypersensitivity to colistimethate Na (colistin) or polymyxin B.
Special Precautions
Discontinue in case of allergic reactions. Consider concomitant use w/ antibacterials to prevent the emergence of resistance. Monitor renal function at the start of treatment & regularly during treatment; for perioral paraesthesia & paraesthesia in the extremities. Increased risk of nephrotoxicity in patients who are hypovolaemic or w/ potentially nephrotoxic drugs. Neurotoxic effects in high serum conc. Resp arrest may occur following IM administration of therapy. Antibiotic-associated colitis & pseudomembranous colitis; aseptic meningitis; bronchospasm. Discontinue therapy & administer treatment for C. difficile. Should not be given concomitantly w/ drugs that inhibit peristalsis. Patients w/ myasthenia gravis; porphyria. Do not drive or operate machinery if dizziness, confusion or visual disturbance occurs. Renal & hepatic impairment. Pregnancy & lactation. Childn w/ renal impairment. Infants <1 yr.
Adverse Reactions
Neurological events; neurotoxicity; apnoea, transient sensory disturbances (eg, facial paraesthesia & vertigo); renal function adverse effects, nephrotoxicity; hypersensitivity reactions (eg, skin rash, drug fever); inj site irritation; coughing or bronchospasm; sore throat or mouth.
Drug Interactions
Nephrotoxic & neurotoxic agents (eg, gentamicin, amikacin, netilmicin & tobramycin), drugs that inhibit or induce drug metabolizing enzymes, or substrates for renal carrier mechanisms, macrolides (eg, azithromycin & clarithromycin), fluoroquinolones (eg, norfloxacin & ciprofloxacin). Prolong effects of non-depolarising muscle relaxants. Increased risk of nephrotoxicity w/ cephalosporins.
MIMS Class
Other Antibiotics
ATC Classification
J01XB01 - colistin ; Belongs to the class of polymyxins. Used in the systemic treatment of infections.
Kolimycin powd for soln for inj 150 mg
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in